International Niemann–Pick Disease Alliance

MNK Announcement Jan 2021

We have received the following statement from Mallinckrodt Pharmaceuticals, stating their intention to discontinue clinical development of adrabetadex (VTS-270) for Niemann-Pick Type C1 disease (NPC), effective immediately. We understand that this will be very difficult news for many within our global community; please contact your patient group representative if you have any further questions or require additional support at this time.

MNK Announcement - INPDA Jan 2021

A community webinar will take place on Friday 22nd January at 17.30.  The webinar will feature Dr. Steve Romano, Executive Vice President and Chief Scientific Officer at Mallinckrodt, and Dr. Susan VanMeter, Senior Clinical Director, who will address this latest news and take your questions. Please find details below:

Date: Friday, January 22

Time: 17.30- 18.30 GMT 12:30-1:30 p.m. EST

Join Zoom Meeting:

Passcode: 050409

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

Think Again. Think NP-C

Join our international campaign to improve diagnosis of NP-C!